Cyclophosphamide (NSC-26271) Monohydrate

製品コード:S2057 別名:Cytoxan Monohydrate

For research use only.

Cyclophosphamide (NSC-26271, Cytoxan) Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.

Cyclophosphamide (NSC-26271) Monohydrate化学構造

CAS No. 6055-19-2

サイズ 価格(税別)
JPY 18100
JPY 43760

代表番号: 03-5615-9297|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(31)

製品安全説明書

DNA alkylator阻害剤の選択性比較

生物活性

製品説明 Cyclophosphamide (NSC-26271, Cytoxan) Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.
体外試験

Cyclophosphamide (CY) is a chemotherapeutic agent with a dose-dependent, bimodal effect on the immune system. Cyclophosphamide treatment enhances apoptosis and decreases homeostatic proliferation of regulatory T cells. Cyclophosphamide downregulates the expression of GITR and FoxP3, which are involved in the suppressive activity of T(REGs).[1] Cyclophosphamide increases CYP3A4, CYP2C8, and CYP2C9 protein levels in primary human hepatocyte cultures, which thereby enhances their own rates of 4-hydroxylation in the cultured hepatocytes. [2] Cyclophosphamide has produced mutations in base-pair substituting strains of Salmonella tryphimurium in the presence of metabolic activation, but it has been shown to be negative in the E. coli chromotest. Cyclophosphamide has been shown to produce gene mutations, chromosome aberrations, micronuclei and sister chromatid exchanges in a variety of cultured cells in the presence of metabolic activation as well as sister chromatid exchanges without metabolic activation. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BALB/c 3T3 cells M1T6WWN6fG:2b4jpZ4l1gSCjc4PhfS=> NGLFOGFKdiC4aYTyc{BkgXSxdH;4bYNqfHlid3HzJIV3[Wy3YYTl[EBqdiCvb4Xz[UBmdWK{eX:gRmFNSi:lIEPUN{Bk\WyuczygTWM2OD1|Nz62JO69VQ>? NILBcWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97OEezOFEzLz57OEezOFEzRC:jPh?=
HL60 cells NV\uXWFbS3m2b4TvfIlkcXS7IHHzd4F6 MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF05Njd7IN88US=> M4\qUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEWwN|A{Lz5{MEi1NFMxOzxxYU6=
BALB/c 3T3 NFjPNlhEgXSxdH;4bYNqfHliYYPzZZk> MXjJckB3cXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBDSUyEL3OgN3Q{KGOnbHzzMEBKSzVyIE2gN|cvPiEQvF2u NGj3VXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi95OEe3NVUxLz55OEe3NVUxRC:jPh?=
T-cells MWjJcY12dm:|dYDwdoV{e2m4ZTDhd5NigQ>? M4jJPVExOCCvZz;r[y=> NUnhRoo{QCCmYYnz NFXhU3dKdW23bn;zeZBxemW|c3n2[UBi[3Srdnn0fUBi\2GrboP0JG1CXi1zIHnu[oVkfGWmIFLBUGIw[yCvb4Xz[UBie3Onc4Pl[EBieyCWIHPlcIx{KHO3cIDy[ZN{cW:wIHH0JFExOCCvZz;r[{whcXBidILlZZRm\CB6IHThfZMh[mWob4LlJIlv\mWldHnvckBnd3JiNDD3[YVseyCvZXHzeZJm\CBzNDDkZZl{KHCxc4SgbY5n\WO2aX;uJIJ6KG[ub4egZ5l1d22ndIL5 NVTke|VRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOlgxQDVpPkG4NlY5ODh3PD;hQi=>
B-cells M1TlNmludXWwb4P1dJBz\XO|aY\lJIF{e2G7 MVOxNFAhdWdxa3e= NInadIc5KGSjeYO= MnLiTY1ufW6xc4XwdJJme3OrdnWgZYN1cX[rdImgZYdicW6|dDDNRXYuOSCrbn\lZ5Rm\CCEQVzCM4MhdW:3c3WgZZN{\XO|ZXSgZZMhSiClZXzsd{B{fXCycnXzd4lwdiCjdDCxNFAhdWdxa3esJIlxKHS{ZXH0[YQhQCCmYYnzJIJm\m:{ZTDpcoZm[3Srb36g[o9zKDRid3Xlb5MhdWWjc4Xy[YQhOTRiZHH5d{Bxd3O2IHnu[oVkfGmxbjDifUBndG:5IHP5eI9u\XS{eR?= M3;1XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Mk[4NFg2Lz5zOEK2PFA5PTxxYU6=
U87 MG M2PJPGFvfGm2dX3vdkBie3OjeR?= MXu4NEBu\y:tZx?= MkfvRY51cXS3bX;yJIFkfGm4aYT5JIlvKGi3bXHuJHU5PyCPRzDj[YxteyC6ZX7v[5Ji\nSnZDDtc5V{\SCjdDC4NEBu\y:tZzygbZYh[WSvaX7pd5RmemWmIHnuJHEzTCC6IEWgd4Np\WS3bHW= NWDNSnZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0OVA1PTZpPkG4OFUxPDV4PD;hQi=>
MX1 NEfYZ4JCdnSrdIXtc5Ih[XO|YYm= MYSxNlAhdWdxa3e= NEXTXJJ2eCC2bzCzJJdm\Wu| NGX3dFRCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNXFEh[2WubIOgfIVvd2e{YX\0[YQhcW5iboXk[UBud3W|ZTDh[Ip2fmGwdDDtc4RmdCCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBud3W|ZTDzeZJ3cX[jbDD0bY1mKGG2IEGyNEBu\y:tZzygdI8hSkmGIH3lZZN2emWmIIXwJJRwKDNid3Xlb5M> M2jJPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyN{K2OVEzLz5{MEeyOlUyOjxxYU6=
U87MG M1n5b2FvfGmlYX7j[ZIh[XO|YYm= MUW4NEBu\y:tZx?= MkjQOkBl[Xm| M2GxdGFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDheIh6dWmlIH3veZNmKGG|c3Xzd4VlKGG|IIT1cY9zKHO3cIDy[ZN{cW:wIHH0JFgxKG2pL3vnMEBqfiCTMlSg[o9zKDZiZHH5dy=> NGPmfm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGwOlM4Pyd-MkGxNFY{Pzd:L3G+
NCI-H522 NXuycoxTSW62aYT1cY9zKGG|c3H5 MlTpOVAhdWdxa3e= MYCyPEBl[Xm| MkfURY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg2OjJiY3XscJMhgGWwb3fyZYZ1\WRiaX6gRoFt[i:lIH71[IUhdW:3c3WgZZN{\XO|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhPTBibXevb4ctKGmpIHHkcYlvcXO2ZYLl[EBwdmOnIHThbYx6KG[xcjCyPEBl[Xm|IILlcIF1cX[nIITvJINwdnS{b3y= NHzNS2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC5Nlg3OCd-MkiwPVI5PjB:L3G+
U2932 MVrBcpRqfHWvb4KgZZN{[Xl? MUO1NEBu\y:tZx?= NYfwZ|doPSClb37z[YN2fGm4ZTDkZZl{ NIm4NWxCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVNlk{OiClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjD0eY1weiCkdYLk[Y4h[XRiNUCgcYcwc2duIHnwJIFldWmwaYP0[ZJm\CCob4KgOUBkd26|ZXP1eIl3\SCmYYnzJI1m[XO3cnXkJJVxKHSxIHThfUA1OCCyb4P0JINmdGxiaX7q[YN1cW:w NFLhTXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[wOVU6Oyd-Mki2NFU2QTN:L3G+
MDA-MB-231 M1PN[WN6fG:2b4jpZ4l1gSCjc4PhfS=> MVO0PEBpeg>? NH\mfXdEgXSxdH;4bYNqfHliYXfhbY5{fCCKb33vJJNieGmnboOgLIh2dWGwKTDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDR6IHjyJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEmg{txONg>? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4PE8oRkOqRV3CUFww[T5?
K562 NYnTdpI1S3m2b4TvfIlkcXS7IHHzd4F6 NIDpSnc1QCCqch?= MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBJd22xIIPhdIlmdnNiKHj1cYFvMSCNNU[yJINmdGy|IHHmeIVzKDR6IHjyJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUWg{txONg>? NETBVWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5QC9pPlPoSW1DVDxxYU6=
K562 NWOweIRTSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MY[0PEBpeg>? MknERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDIc41wKHOjcHnlcpMhMGi3bXHuLUBMPTZ{IHPlcIx{KGGodHXyJFQ5KGi{IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOTV|IN88UU4> MniyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFgwLz6FaFXNRmw9N2F-
MCF7 MXXDfZRwfG:6aXPpeJkh[XO|YYm= NGXWWFg1QCCqch?= MoX0R5l1d3SxeHnjbZR6KGGpYXnud5QhUG:vbzDzZZBq\W6|IDjoeY1idiliTVPGO{Bk\WyuczDh[pRmeiB2ODDodkBjgSC2conwZY4h[my3ZTDhd5NigSxiSVO1NEA:KDBwMU[g{txONg>? NWH5RmU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDhxJ{7DbGVOSkx:L3G+
HepG2 M4XTXGN6fG:2b4jpZ4l1gSCjc4PhfS=> MVG0PEBpeg>? M{jyZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEixbX:gd4FxcWWwczCobJVu[W5rIFjldGczKGOnbHzzJIFnfGW{IES4JIhzKGK7IF3UWEBie3OjeTygTWM2OCB;IECuNlQh|ryPLh?= NXvTTYZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDhxJ{7DbGVOSkx:L3G+
アッセイ
Methods Test Index PMID
Western blot PTEN / pAkt / Caspase 3 / GAPDH ; Caspase 3 / Cleaved-Caspase 3 / Cleaved-PARP / Tubulin ; Nuclear AIF / Cytosolic AIF / TBP / GAPDH ; LC3B I / LC3B II / GAPDH 23874108 31429028
Growth inhibition assay Cell Viability ; Tumor Volume ; Tumor Volume 31429028 24681847 21069336
IHC tumor cell invasion ; TUNEL / Caspase 3 ; PTEN / pAkt / PCNA ; ovary of mice ; Caspase-3 23874108 32308430
Immunofluorescence pAKT / pERK ; Ki-67 / UPK3 / KRT5 / pERK ; Ki-67 / KRT14 / KRT5 ; autophagy levels 31654636 31429028
体内試験 Cyclophosphamide has also produced chromosome damage and micronuclei in rats, mice and Chinese hamsters, and gene mutations in the mouse spot test and in the transgenic lacZ construct of Muta Mouse. [3] Cyclophosphamide, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhances the vaccine's potential to delay tumor growth in neu transgenic mice. Cyclophosphamide mediates its effects by enhancing the efficacy of the vaccine rather than via a direct cytolytic effect on cancer cells. [4]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外

化学情報

分子量 279.1
化学式

C7H15Cl2N2O2P.H2O

CAS No. 6055-19-2
Storage 3年 -20°C
2年 -80°C in solvent
Smiles C1CNP(=O)(OC1)N(CCCl)CCCl.O

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05290662 Recruiting Drug: oNKord®|Drug: Cyclophosphamide/Fludarabine (Cy/Flu) AML Glycostem Therapeutics BV June 2022 --
NCT05128617 Recruiting Drug: Epirubicin-cyclophosphamide|Drug: Paclitaxel Breast Cancer Institut de cancérologie Strasbourg Europe|Université de Strasbourg - Unité de Recherche 3072 - Mitochondries Stress oxydant Protection musculaire November 4 2021 --

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問1:
Why S2057 Cyclophosphamide Monohydrate shows no activity in vitro assays?

回答
Cyclophoshamide is a prodrug and needs Pytochrome P450 to convert it to the active form: 4-hydroxy cyclophosphamide. It is widely used in vivo, if you are going to use it in vitro, you'll have to supplement Pytochrome P450 exogenously.

Tags: Cyclophosphamide (NSC-26271) Monohydrateを買う | Cyclophosphamide (NSC-26271) Monohydrate ic50 | Cyclophosphamide (NSC-26271) Monohydrate供給者 | Cyclophosphamide (NSC-26271) Monohydrateを購入する | Cyclophosphamide (NSC-26271) Monohydrate費用 | Cyclophosphamide (NSC-26271) Monohydrate生産者 | オーダーCyclophosphamide (NSC-26271) Monohydrate | Cyclophosphamide (NSC-26271) Monohydrate化学構造 | Cyclophosphamide (NSC-26271) Monohydrate分子量 | Cyclophosphamide (NSC-26271) Monohydrate代理店